# Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

> **NCT00878722** · PHASE1,PHASE2 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 41 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** PXD101
- **DRUG:** idarubicin

## Key facts

- **NCT ID:** NCT00878722
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-05
- **Final completion:** 2012-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878722, "Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00878722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*